Related Experiment Video
Updated: Jun 11, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Mohs Micrographic Surgery With Melanocytic Immunostains for T1a/b Invasive Melanoma Yields <1% Local Recurrence and
Anagha Bangalore Kumar1, Thomas Trischman1, Eucabeth Asamoah1
1Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
Background:
The use of Mohs micrographic surgery with melanocytic immunostains (MMS-I) for cutaneous melanoma is increasing.
Objective:
To assess local recurrence, melanoma-specific death rates in patients with invasive melanoma treated with MMS-I.
Materials And Methods:
A single-center retrospective review of patients with invasive melanoma treated with MMS-I from January 2008 to December 2018.
Results:
Three hundred fifty-two patients (359 melanomas) were included. The median age was 71 years; most patients were male (252%; 71.6%). Most tumors were T1a/b (341, 95%), H/N (322; 89.7%), and lentigo maligna subtype (281, 78.3%). At a median follow-up of 4.3 years, local recurrence rates were 1.4% (5) and 0.9% (3) among all-stage and T1a/b tumors, respectively. There were 3 melanoma-related deaths (0.9%).
Conclusion:
MMS-I is associated with <1% risk of local recurrence and disease-specific mortality for T1a/b melanomas.
